Although several vaccines are now being tested in clinical Phase I and II trials (MSP-1, MSP-2, and MSP-3) or even have completed the pivotal Phase III clinical testing (RTS/S), the efficacies of these vaccines have been low, with limited impact against clinical malaria [5, 6]. The gene discussed is ATAD1; the disease is malaria.